anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
We are currently witnessing the advent of new diagnostic tools and therapies for heart diseases, but,without serious scientific consensus on fundamental questions about normal and diseased heart structure and function. During the last decade, three successive, international, multidisciplinary symposia were organized in order to setup fundamental research principles, which would allow us to make a significant step forward in understanding heart structure and function. (Kocica MJ et al., 2006) Helical ventricular myocardial band (HVMB, Figure 2-1) of Torrent-Guasp is the revolutionary new concept in understanding global, three-dimensional, functional architecture of the ventricular myocardium. This concept defines the principal, cumulative vectors, integrating the tissue architecture (i.e. form) and net forces developed (i.e. function) within the ventricular mass. Helical ventricular myocardial band of Torrent-Guasp may also, hopefully, allow overcoming some difficulties encountered in contemporary efforts to create a comprehensive mathematical model of the heart.

Within the ventricular mass, size, shape, connections and orientation in a three-dimensional space of every single constituent determine its functional behavior. This kind of spatial dependence allows the ventricular myocardial mass to be considered as the source of interdependent vectorial forces (i.e.

electrical and mechanical), being generated on different length and time scales. The ultimate net result of these vectorial forces is to translate uniaxial sarcomere shortening into efficient three-dimensional deformation of the ventricular cavity. The complex architecture of the ventricular mass creates multiple inhomogeneities of electrical and mechanical loads at the cellular and the microscopic tissue level, that cause cardiac function to be 'stochastic in nature'. However, at macroscopic (i.e. organ) level, these stochastic events become average and appear consistent with a continuous medium. This dialectic coexistence of complexity and simplicity, discreetness and continuity suggests the existence of certain rule-based assignment, which 'may be applied equally well to all the ventricular myocardial fibers', enabling the ventricular myocardial mass to assemble abundant, dynamic, stochastic vectorial forces and produce apparently smooth, averaged, continuous, global response.
Patients will be treated a maximum of 8 cycles or until the patient has evidence of a response, progressive disease, or until intolerable toxicity develops. Patients with a complete response will receive an additional 2 cycles of treatment (not to exceed 8 cycles). Drug order is gemcitabine, mitoxantrone, and rituximab.
PURPOSE:An oily gelatinous cosmetic, containing two kinds of clay minerals treated with a nonionic surfactant and both a cationic surfactant and a nonionic surfactant and an oil and having improved stability, water repellency and feeling of use. CONSTITUTION:A cosmetic containing (A) a clay mineral treated with a nonionic surfactant having within 2-16, preferably 3-12HLB value range, preferably ethylene oxide addition type, e.g. POE addition ether ester type, (B) a clay mineral treated with a cationic surfactant, e.g. quaternary ammonium salt type, and a nonionic surfactant and (C) a general oil used for the cosmetic. The amounts of the components are preferably as follows; 1-20wt% component (A), 1-40wt% component (B) and 10-80wt% component (C). A colloidal hydrous aluminum silicate, e.g. montmorillonite or synthetic mica, having three-layer structure and swelling in water is used as the clay mineral.
Oxytocin 20 IE in 500 ml G Na intravenous infusion over 6 hours (GlucoSalin 2:1; 2/3 glucose 5%+1/3 NaCl 0.9%), Sintetica-Bioren, Switzerland, after birth of the baby. For blinding purposes a 3ml NaCl 0.9% syringe is administered intravenously after birth of the baby as well.
Intranasal (IN) nanoparticles - 1.0 micrograms. The study is planned to include 1 dose of APH 1105 / 1.0 µg, administered twice a week for 12 weeks, for a total of 24 doses.
FIELD: medicine. SUBSTANCE: present invention discloses peptide of formula: H-11e-Glu-Trp-OH having effect on regeneration of homogenic and immune systems. Pharmaceutical composition comprises effective amount of said peptide. Composition can be in any form and is suitable for oral, nasal, external and injection administration. Said composition preferably comprises 0.001-0.01 wt % peptide. The present invention widens range of agents having high activity, low toxicity and no side effect. EFFECT: improved properties of the pharmaceutical composition. 6 cl, 2 dwg, 7 ex, 12 tbl
Up to 250 children and adolescents ages 5 to 18, meeting DSM IV criteria for schizophrenia, schizoaffective disorder, and psychotic disorder not otherwise specified, are currently under study in our group. The purpose of this protocol is to allow systematic outpatient, and subsequent inpatient, screening evaluation to establish an accurate diagnosis for research, obtain clinical and neurobiological research measurements, evaluate the patient s response to open treatment with antipsychotic(s), and allow longitudinal follow-up. Subjects and first-degree relatives may then be enrolled in Protocol 89-M-0006, Brain Imaging of Childhood Onset Psychiatric Disorders, Endocrine Disorders and Healthy Controls, and Protocol 84-M-0050, Biochemical, Physiological, and Psychological Measures in Normal Controls and Relatives of Psychiatric Patients. If additional research protocols are available, this screening protocol will represent an entry point for them.

The evaluation process will include a one-day outpatient psychiatric screening interview with proband and family. If it is thought that the child is likely to meet criteria for childhood onset psychoses, an inpatient evaluation will then be offered for clarifying the diagnosis. This may involve: 1) Up to 3 weeks of inpatient observation on the child s current medication regimen. 2) Tapering of psychotropic medications (1-4 weeks, depending upon type and dosage). 3) Observation for up to 3 weeks drug free, in order to confirm the diagnosis, and 4) Once the diagnosis is confirmed, two to ten weeks of treatment with antipsychotic(s); 5) Discharge to the care of his/her community psychiatrist. Treatment will be guided by what is considered the subject s best clinical interest. During the inpatient stay, or occasionally as part of the outpatient screening, we will obtain neurocognitive testing, research blood draws including blood for genetic testing of the proband, and a research brain MRI scan. A skin biopsy may be obtained either during the inpatient stay or a follow up visit.

This protocol also includes a study 100 non-schizophrenic children ages 6-13 with psychotic symptoms (e.g. hallucinations or delusions) to extend our studies of early neuro-developmental biomarkers and of the factors that either promote or stop the progression to full schizophrenia (resilience or conversion factors). These children will be recruited from the local community, evaluated as outpatients and followed prospectively for five years. Measures will include diagnostic interviews, clinical ratings, neurocognitive testing, anatomic and functional imaging, and blood for routine and genetic testing.
<P>PROBLEM TO BE SOLVED: To provide a lipstick composition emphasizing a red color with a small amount of a dye without applying a load to lips, to provide a lipstick composition thickly applicable even with the small amount of the dye and further to provide a lipstick composition having skin regeneration promoting effects of damaged lips.  <P>SOLUTION: The lipstick composition is obtained by adding nano-powder of pearls and reducing the amount of the dye used. The lipstick composition is prepared by regulating the nano-powder to ≤3.0 mass% based on the total mass of the lipstick composition. The lipstick composition is obtained by mixing the pearl powder having the particle diameters of the μm order and nano-order. The lipstick composition is prepared by adding a trace amount of hydrolyzed eggshell membrane.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
BRYHALI (halobetasol propionate) lotion contains a corticosteroid, halobetasol propionate, as the active ingredient in a white to off-white lotion formulation intended for topical use. 

Halobetasol propionate is a synthetic corticosteroid. The chemical name for halobetasol propionate is 21-chloro-6α, 9-difluoro-11β, 17-dihydroxy-16β-methylpregna-1, 4-diene-3, 20 –dione, 17-propionate. Halobetasol propionate is a white to off-white crystalline powder with a molecular weight of 484.96 and a molecular formula of C25H31ClF2O5. It is practically insoluble in water and freely soluble in dichloromethane and in acetone. The structural formula for halobetasol propionate is represented below:

Each gram of BRYHALI Lotion contains 0.1 mg (0.01%) halobetasol propionate in a white to off-white lotion base consisting of carbomer copolymer type B, carbomer homopolymer type A, diethyl sebacate, edetate disodium dihydrate, light mineral oil, methylparaben, propylparaben, purified water, sodium hydroxide, sorbitan monooleate and sorbitol solution, 70%.
Preliminary data from the investigators' laboratory demonstrate a negative relationship between hemoglobin A1c (HbA1c) and ETBR function, supporting ETBR may be dysfunctional in the presence of T1D. Using near infrared spectroscopy (NIRS) to non-invasively assess muscle function, the investigators have also observed reduced skeletal muscle mitochondrial function in people with T1D compared to healthy controls. In addition, reduced circulating Sirt1 is associated with both ETBR and skeletal muscle mitochondrial dysfunction in the general population. For the current application, the investigators propose to utilize intradermal microdialysis and NIRS as unique, novel, and minimally invasive methods to investigate ETBR and skeletal muscle mitochondrial function, respectively, in people with T1D. Accordingly, the central hypothesis is that increasing circulating Sirt1 with oral supplementation of resveratrol will improve both ETBR function and mitochondrial skeletal muscle function, reducing overall CVD risk (Figure 1). The investigators will test this hypothesis with the following specific aims:

Aim 1: To test the hypothesis that an increase in Sirt1 will improve ETBR function in people with T1D. The investigators will evaluate ETBR function and circulating Sirt1 at baseline and after a 12-week treatment of resveratrol or placebo. Based on preliminary data, the investigators predict that people with T1D will have ETBR dysfunction compared to controls. In addition, the investigators predict that increasing Sirt1 following resveratrol treatment will improve ETBR function, whereas no change will occur with placebo.

Aim 2: To test the hypothesis that an increase in Sirt1 will improve skeletal muscle mitochondrial function and lower HbA1c in people with T1D. A non-invasive assessment of skeletal muscle function will be performed on people with T1D before and after 12-weeks of treatment with resveratrol or placebo. Compared to controls, the investigators predict that people with T1D will have skeletal muscle dysfunction. Following 12 weeks of resveratrol, the investigators predict that the increase in circulating Sirt1 will improve skeletal muscle function. Additionally, the investigators predict the improved skeletal muscle function will contribute to a subsequent decrease in HbA1c in people with T1D.
The invention relates to an external-application medicine used for treating vasculitis, and a preparation method thereof. The medicine is prepared from the raw materials of, by weight, 7-10 parts of Japanese thistle, 6-9 parts of common thistle, 1-2.5 parts of ligusticum, 2-5 parts of argy wormwood leaf, 32-58 parts of fresh ginger, 2-5 parts of xanthium strumarium, 0.2-0.5 parts of castor oil, 0.56-0.86 parts of capparis spinosa, 2-5 parts of speranskia tuberculata, 5-8 parts of imperatae rhizome, and 1-2.5 parts of drug sweetflag rhizome. With the medicine, vasculitis can be effectively treated. The medicine has the effects of heat clearing, detoxifying, meridian warming, cold dispelling, and body injury repairing. The medicine has low toxic and side effects, and has low cost. The medicine provides a good curative effect.
PURPOSE: To prepare a composition, comprising an ultraviolet screening agent selected from specific pyrimidine derivatives and specified compounds, capable of inducing and stimulating the hair growth and delaying the hair loss and useful for alopecia. CONSTITUTION: This composition comprises at least one pyrimidine derivative of formula I [R1 is a group of formula II (R3 . and R4 are each H, a lower cycloalkyl, an alkyl, an alkenyl, etc.), etc.; R2 is H, a lower haloarylalkyl, an alkyl, an alkenyl, etc.] and addition salts with acids and an ultraviolet screening agent selected from 2-hydroxy-4-methoxybenzophenone, 2-ehylhexyl p- dimethylaminobenzoate, pentyl p-dimethylaminobenzoate, 2-ethylhexyl p- methoxycinnamate, etc., and a mixture thereof in an amount of 0.1-10wt.%, preferably 0.3-4wt.% based on the total weight of the composition in a medium (e.g. ethyl alcohol can especially be used in an aqueous medium).
PURPOSE: A composition containing a Hedyotis diffusa extract for preventing and treating obesity is provided to activate AMPK(5' AMP-activated protein kinase) and to effectively control body weight without side effect or toxicity. CONSTITUTION: A pharmaceutical composition for preventing and treating obesity contains a Hedyotis diffusa extract as an active ingredient. A health functional food for preventing and treating obesity contains the extract as an active ingredient. The pharmaceutical composition contains a compound among compound of chemical formulas 1-3 as an active ingredient. A method for preparing the extract comprises: a step of extracting Hedyotis diffusa with water, alcohol of C1-C4, or a mixture thereof; and a step of fractioning the extract with dichloromethane. The method further comprises a step of fractioning the dichloromethane fraction layer with ethyl acetate.
The supply of drugs into the human body has developed novel alternatives of medical dosage, where the controlled and continuous dosing still being a challenge. The device for the automatic monitoring of glucose and controlled dosage of inulin through microneedles and microfluidic channels and method for controlling the same allows drugs to be uniformly released through a microfluidic device, which distributes the drug in the microneedles for being subsequently released in a transdermal form. The device is designed to be located in patients with inulin deficiencies, facilitating the control of the drug in the patient’s life according to the clinical history of the same. The design of the device involves the modularity thereof for facilitating the everyday life of the patient. The six modules of the device include a system for taking blood samples, a sensor, a control module, a flow and pumping divider system, a microneedles patch and a user-control interface. The device includes these modules for the controlled dosage of inulin, through a patch of microneedles which is exchangeable every 10 blood samples, including a refillable deposit that is fastened to the arm of the patient for the continuous dosing and monitoring.
Materials derived from Citrus plants can be administered orally to humans for the purpose of producing or maintaining weight loss as well as for improving the person's physical performance and increasing the person's lean muscle mass. The Citrus materials include those portions of the plant that are normally considered waste or inedible, such as the leaves, peel, and immature, unripe fruit. The materials contain at least one of the alkaloids from the group consisting of synephrine, hordenine, octopamine, tyramine and N-methyltyramine (1). Two species, Citrus aurantium and Citrus reticulata, are particularly useful. The materials can be administered in their natural form or as extracts, and can be administered in various ways including capsules and tablets. The Citrus materials may also be used as a tea. For weight loss and weight control, the materials can be administered concurrently with caloric restriction or in the absence of caloric restriction. The materials may also be administered for the purpose of increasing muscle mass concurrently with a high protein diet as well as with an exercise program.
OBJECTIVE: To explore the regulatory role of Abelson interactor 2 (ABI2) in progression and prognosis of gastric cancer.
METHODS: TIMER2.0, GEPIA, Kaplan-Meier Plotter and DAVID databases were used to analyze ABI2 expression in pancancer and its association with the prognosis of gastric cancer. Gastric cancer and adjacent tissues from 120 patients undergoing radical gastrectomy in our hospital between January, 2016 and October, 2018 were examined for ABI2 expression and its correlation with disease progression and prognosis. MGC-803 cell models of ABI2 knockdown and overexpression were established for observing the changes in cell proliferation, migration, and invasion, and the impact of ABI2 expression modulation on xenograft growth was evaluated in nude mice.
RESULTS: Database analysis and examination of the clinical samples showed that ABI2 was highly expressed in gastric cancer tissues. Survival analysis suggested that gastric cancer patients with a high expression of ABI2 had a reduced postoperative 5-year survival rate (P < 0.0001), and further Cox univariate and multivariate survival analyses indicated that a high ABI2 expression was an independent risk factor affecting the patients survival outcomes (P=0.022, HR=1.887, 95% CI: 1.096-3.249). Enrichment analysis suggested the involvement of ABI2 in Wnt signaling. In MGC-803 cells, ABI2 overexpression promoted cell proliferation and xenograft growth in nude mice, increased the expressions of vimentin and N-cadherin, and lowered E-cadherin expression, while ABI2 knockdown produced the opposite effects. Mechanistic analysis revealed that ABI2 overexpression promoted the expressions of Wnt2 and β-catenin in both MGC-803 cells and the xenografts, and their expressions were significantly lowered by ABI2 knockdown.
CONCLUSION: ABI2 is highly expressed in gastric cancer, which affects long-term prognosis of the patients, possible due to its regulatory effect on Wnt signaling to promote proliferation, migration and invasion of gastric cancer cells.
BACKGROUND: Cardiac troponin T (cTnT) is key in diagnosing myocardial infarction (MI) but is also elevated in end-stage renal disease (ESRD) patients. Specific larger cTnT proteoforms were identified for the acute phase of MI, while in serum of ESRD patients solely small cTnT fragments were found. However, others allocated this to a pre-analytic effect due to abundant thrombin generation in serum. Therefore, we investigated the effect of various anticoagulation methods on cTnT composition and concentration and compared the cTnT composition of MI and ESRD patients.
METHODS: The agreement of cTnT concentrations between simultaneously collected serum, lithium-heparin (LH) plasma, and ethylenediaminetetraacetic acid (EDTA) plasma was studied using the high-sensitivity (hs-)cTnT immunoassay. cTnT proteoform composition was investigated in a standardized time-dependent manner through spike experiments and in simultaneously collected blood matrixes of MI and ESRD patients.
RESULTS: Excellent hs-cTnT concentration agreements were observed across all blood matrixes (slopes > 0.98; 95% CI, 0.96-1.04). Time-dependent degradation (40 kDa intact:29 kDa fragment:15 to 18 kDa fragments) was found in LH plasma and EDTA plasma, and serum in ratios (%) of 90:10:0, 0:5:95, and 0:0:100, respectively (48 h after blood collection). Moreover, gel filtration chromatography (GFC) profiles illustrated mainly larger cTnT proteoforms in MI patients, while in ESRD patients mainly 15 to 18 kDa fragments were found for all matrices.
CONCLUSIONS: The extent of cTnT degradation in vitro is dependent on the (anti)coagulation method, without impacting hs-cTnT concentrations. Furthermore, mainly larger cTnT proteoforms were present in MI patients, while in ESRD patients mainly small 15 to 18 kDa cTnT fragments were found. These insights are essential when developing a novel hs-cTnT assay targeting larger cTnT proteoforms.
Fourty subjects were randomly allocated into two large groups, the High Fidelity Simulator group and the Low Fidelity Simulator group. Each group was divided into small groups, consist of 2 doctors and 3 nurses. All subjects underwent the same interactive lectures, and two sessions of in-situ simulation according to their assign group. In-situ simulation and debriefing were performed by implementing appropriate personal protective equipment and social distancing. At the end of each simulation session, each group would underwent a debriefing session, which was performed by an experience instructor. The first simulation was aimed to teach participants skills and steps in transporting critically-ill COVID-19 patients according to the hospital check-list. While the second simulation was aimed to assess skills, team work and communication that participants had learned from the previous simulation, by using assessment tools that had been developed before. In addition to comparing each point in the assessment tool between the two groups, the points that had been earned were also added up to get the overall points for total skills, cooperation and communication score. At the end of the session, learner immediate feedback were also collected using an online feedback form, which provided accountability for attendance, content learning, and course evaluation feedback.
The invention discloses a stable oxidized coenzyme I preparation, which comprises the following raw materials in parts by weight: 1 part of oxidized coenzyme I and 5-15 parts of lactose. The invention also discloses a preparation method of the stable oxidized coenzyme I preparation, which comprises the following steps: S1. adding lactose to injection water, stirring until lactose is dissolved, adding medical activated carbon and stirring to obtain a solution A; adding injection water, adjusting the temperature to 20-25 DEG C, adding the oxidized coenzyme I and stirring until oxidized coenzyme I is dissolved to obtain a solution B; dropwise adding a NaOH aqueous solution, and adding injection water to obtain a solution C, wherein the pH of the solution C is 5.0-5.5; S2. filtering and filling; and S3. Freeze-drying. The stable oxidized coenzyme I preparation is simple in components, few in medical auxiliary material variety, and good in stability; and the preparation method is simple in operation, short in freeze drying time, and suitable for industrial production, and realizes energy-saving and consumption-reducing effects.